TargetBeta
PRKDC
protein kinase, DNA-activated, catalytic subunit · also DNPK1, p350, DNAPK, XRCC7 · Armadillo like helical domain containing
2 programs in company-led studies act on PRKDC, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| AMO959 | Novartis | phase 2 | 22 running | – | the company's pipeline |
| bosmolisibrule | Boryung Pharmaceutical | phase 2 | 21 running | – | NCIt |
Conditions their studies are in
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, T-Cell, Peripheral, 1 program
- Prostatic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Sep 2027bosmolisib · Boryung Pharmaceutical · phase 2 · NCT07180771
- Jul 10, 2028AMO959 · Novartis · phase 2 · NCT07226986
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.